LENZ Therapeutics (NASDAQ:LENZ) Earns Overweight Rating from Piper Sandler

Piper Sandler restated their overweight rating on shares of LENZ Therapeutics (NASDAQ:LENZ) in a research report sent to investors on Thursday, Benzinga reports. Piper Sandler currently has a $36.00 price objective on the stock.

Separately, HC Wainwright assumed coverage on shares of LENZ Therapeutics in a report on Monday, August 12th. They set a buy rating and a $38.00 target price on the stock. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of Buy and a consensus price target of $35.00.

LENZ Therapeutics Trading Up 0.7 %

Shares of LENZ Therapeutics stock opened at $22.75 on Thursday. The stock has a 50-day moving average price of $20.73. LENZ Therapeutics has a 12-month low of $14.07 and a 12-month high of $29.82.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of LENZ. BML Capital Management LLC purchased a new stake in LENZ Therapeutics in the first quarter valued at approximately $1,427,000. BNP Paribas Financial Markets bought a new position in shares of LENZ Therapeutics in the 1st quarter worth $362,000. Jennison Associates LLC purchased a new stake in shares of LENZ Therapeutics during the 1st quarter valued at $3,009,000. Marquette Asset Management LLC bought a new stake in shares of LENZ Therapeutics during the 1st quarter worth $131,000. Finally, Vanguard Group Inc. purchased a new position in LENZ Therapeutics in the first quarter worth $4,621,000. Hedge funds and other institutional investors own 54.32% of the company’s stock.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.